Dopamine supersensitivity psychosis in schizophrenia: Concepts and implications in clinical practice
The DOI matches its Crossref record; 20 of the 20 references it cites were found in a registry or an index.
Abstract
Dopamine supersensitivity psychosis (DSP) is observed in patients with schizophrenia under antipsychotic treatment, and it is characterized by rebound psychosis, an uncontrollable psychotic episode following a stable state and tardive dyskinesia. DSP, first described in patients taking typical antipsychotics in the late 1970s, sometimes appears even in patients who are treated with current atypical antipsychotics. It was recently demonstrated that DSP can have a negative impact on the long-term prognosis of schizophrenia patients and that DSP could be involved in the etiology of some cases of treatment-resistant schizophrenia. Accumulating evidence suggests that an up-regulation of dopamine D2 receptors (DRD2) in the brain caused by long-term exposure to antipsychotics is related to the DSP phenomenon. The present review describes the clinical characteristics and the etiology of DSP in the era of second-generation antipsychotics for patients with schizophrenia. Based on the mechanism of DSP, several potential treatments for patients presenting with a DSP episode or the dopamine supersensitivity state are also discussed.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
The physiology, signaling, and pharmacology of dopamine receptors
Beaulieu, J.-M., & Gainetdinov, R. R. (2011) · Pharmacological Reviews · doi:10.1124/pr.110.002642 · Cited by 2,763
Antipsychotic drug doses and neuroleptic/dopamine receptors
SEEMAN, P., LEE, T., CHAU-WONG, M., & WONG, K. (1976) · Nature · doi:10.1038/261717a0 · Cited by 1,622
Kapur, S., Zipursky, R., Jones, C., Remington, G., & Houle, S. (2000) · American Journal of Psychiatry · doi:10.1176/appi.ajp.157.4.514 · Cited by 1,090
Atypical antipsychotics: Mechanism of action
Seeman, P. (2002) · The Canadian Journal of Psychiatry · doi:10.1177/070674370204700106 · Cited by 899
Silvestri, S., Seeman, M. V., Negrete, J.-C., Houle, S., Shammi, C. M., Remington, G. J., Kapur, S., Zipursky, R. B., Wilson, A. A., Christensen, B. K., et al. (2000) · Psychopharmacology · doi:10.1007/s002130000532 · Cited by 311 · cited 2×
“However, whether or not the up-regulation of DRD2 actually occurs in a living human’s brain has not yet been demonstrated, although one PET study showed that DRD2 of patients taking antipsychotic(s) may be up-regulated (Silvestri et al., 2000).”
BackgroundNeuroleptic-induced supersensitivity psychosis: clinical and pharmacologic characteristics
(1980) · American Journal of Psychiatry · doi:10.1176/ajp.137.1.16 · Cited by 301 · cited 5×
“Chouinard proposed that TD and DSP could be divided into three stages, classified as a covert or masked state, an overt state, and a persistent state (Chouinard and Jones, 1980).”
BackgroundInfluentialAntipsychotic-Induced Dopamine Supersensitivity Psychosis: Pharmacology, Criteria, and Therapy
Chouinard, G., Samaha, A.-N., Chouinard, V.-A., Peretti, C.-S., Kanahara, N., Takase, M., & Iyo, M. (2017) · Psychotherapy and Psychosomatics · doi:10.1159/000477313 · Cited by 270 · cited 1×
“The reader is also referred to the recent review by Chouinard et al. (2017) to explore the relevant knowledge gained in animal studies and to see newly proposed DSP criteria that are suitable for the era of atypical antipsychotics.”
BackgroundSelf-citationSamaha, A.-N., Seeman, P., Stewart, J., Rajabi, H., & Kapur, S. (2007) · The Journal of Neuroscience · doi:10.1523/jneurosci.5416-06.2007 · Cited by 262
Seeman, P., & Tallerico, T. (1999) · American Journal of Psychiatry · doi:10.1176/ajp.156.6.876 · Cited by 237 · cited 2×
“, quetiapine or clozapine) is reduced or fully tapered off, both of which are recognized to result in typical rebound psychotic episodes (Margolese et al., 2002; Moncrieff, 2006; Seeman and Tallerico, 1999; Takase et al., 2015).”
BackgroundMoncrieff, J. (2006) · Acta Psychiatrica Scandinavica · doi:10.1111/j.1600-0447.2006.00787.x · Cited by 231 · cited 2×
“, quetiapine or clozapine) is reduced or fully tapered off, both of which are recognized to result in typical rebound psychotic episodes (Margolese et al., 2002; Moncrieff, 2006; Seeman and Tallerico, 1999; Takase et al., 2015).”
Background
Cited by
What is the risk‐benefit ratio of long‐term antipsychotic treatment in people with schizophrenia?
Correll, C. U., Rubio, J. M., & Kane, J. M. (2018) · World Psychiatry · doi:10.1002/wps.20516 · Cited by 324
Lerner, A., & Klein, M. (2019) · Brain Communications · doi:10.1093/braincomms/fcz025 · Cited by 89
Reversal of Dopamine Supersensitivity as a Mechanism of Action of Clozapine
Kim, D. D., Barr, A. M., Honer, W. G., & Procyshyn, R. M. (2018) · Psychotherapy and Psychosomatics · doi:10.1159/000491700 · Cited by 14
Metadata
- Authors
- Nakata, Y., Kanahara, N., & Iyo, M.
- Venue
- Journal of Psychopharmacology
- Publisher
- SAGE Publications
- Published
- 2017-09-19
- Volume
- 31
- Issue
- 12
- Pages
- 1511-1518
- ISSN
- 0269-8811 (ISSN-L)
- 1461-7285
- OpenAlex
- W2754884525
- Cited by
- 53
- References
- 20
- FWCI
- 3.59
- Type
- journal article
- Language
- en
- Open access
- closed
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
How to cite
Cite CoChat for the checks on this page, and the paper for its own findings.
- This page
- CoChat. (2026). Citation check: Dopamine supersensitivity psychosis in schizophrenia: Concepts and implications in clinical practice. https://app.cochat.ai/papers/10.1177/0269881117728428
- The paper
- Nakata, Y., Kanahara, N., & Iyo, M. (2017). Dopamine supersensitivity psychosis in schizophrenia: Concepts and implications in clinical practice. Journal of Psychopharmacology. https://doi.org/10.1177/0269881117728428
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.